<Record>
<Term>BMS-599626</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Enzyme Inhibitor/Protein Kinase Inhibitor/Tyrosine Kinase Inhibitor/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor/BMS-599626</ClassificationPath>
<BroaderTerm>BMS-599626</BroaderTerm>
<BroaderTerm>Tyrosine Kinase Inhibitor</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Enzyme Inhibitor</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<BroaderTerm>Protein Kinase Inhibitor</BroaderTerm>
<Synonym>BMS-599626</Synonym>
<Description>An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)</Description>
<Source>NCI Thesaurus</Source>
</Record>
